BridgeBio's stock jumps 3.8% premarket after company announces $250 million PIPE financing led by Qatari sovereign fund
BridgeBio Pharma Inc.'s stock (BBIO) jumped 3.8% in premarket trade Monday, after the company announced a $250 million private investment in public equity, or PIPE, equity offering led by the Qatari sovereign fund. The Palo Alto, Calif.-based biotech, which specializes in treatments for genetic diseases and cancers, said the placement of 9.2 million shares priced at Friday's closing price of $27.27 a share. Other participants include four of the biggest investment management companies in the U.S. and a number of big institutional investors and existing investors. "The company completed this targeted and strategic raise in order to provide an entry for new long-term shareholders," BridgeBio said in a statement. "The company also continues to explore additional strategic options to fund the business." TD Cowen, Mizuho and KKR Capital Markets were joint placement agents on the deal. The stock has gained 258% in the year to date, while the S&P 500 has gained 12.5%. See also: BridgeBio's stock rockets 66% on news of positive results from late-stage trial of ATTR-CM treatment
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-25-23 0744ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom